Russell Investments Group Ltd. boosted its position in Fluidigm Corporation (NASDAQ:FLDM) by 4.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,348,419 shares of the medical research company’s stock after buying an additional 89,482 shares during the period. Russell Investments Group Ltd. owned about 8.02% of Fluidigm Corporation worth $9,485,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in FLDM. American International Group Inc. boosted its position in Fluidigm Corporation by 7.1% in the first quarter. American International Group Inc. now owns 17,907 shares of the medical research company’s stock worth $102,000 after buying an additional 1,187 shares in the last quarter. AQR Capital Management LLC purchased a new position in Fluidigm Corporation during the fourth quarter worth approximately $119,000. Stoneridge Investment Partners LLC boosted its position in Fluidigm Corporation by 4.2% in the first quarter. Stoneridge Investment Partners LLC now owns 25,293 shares of the medical research company’s stock worth $144,000 after buying an additional 1,013 shares in the last quarter. Wells Fargo & Company MN boosted its position in Fluidigm Corporation by 15.0% in the first quarter. Wells Fargo & Company MN now owns 25,521 shares of the medical research company’s stock worth $146,000 after buying an additional 3,327 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY boosted its position in Fluidigm Corporation by 3.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 20,789 shares of the medical research company’s stock worth $151,000 after buying an additional 632 shares in the last quarter. 91.41% of the stock is owned by hedge funds and other institutional investors.
Fluidigm Corporation (NASDAQ:FLDM) traded up 0.85% during trading on Wednesday, hitting $3.58. 71,670 shares of the company were exchanged. Fluidigm Corporation has a 12 month low of $2.52 and a 12 month high of $9.65. The stock’s 50-day moving average is $3.73 and its 200-day moving average is $4.89. The company’s market capitalization is $105.30 million.
Fluidigm Corporation (NASDAQ:FLDM) last announced its earnings results on Thursday, August 3rd. The medical research company reported ($0.58) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.60) by $0.02. The company had revenue of $23.90 million during the quarter, compared to analyst estimates of $23.50 million. Fluidigm Corporation had a negative net margin of 74.05% and a negative return on equity of 121.04%. Fluidigm Corporation’s revenue was down 15.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.63) earnings per share. Equities research analysts anticipate that Fluidigm Corporation will post ($2.19) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Fluidigm Corporation (FLDM) Stake Boosted by Russell Investments Group Ltd.” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/08/16/fluidigm-corporation-fldm-stake-boosted-by-russell-investments-group-ltd.html.
A number of research firms recently commented on FLDM. Zacks Investment Research raised shares of Fluidigm Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, June 1st. ValuEngine cut shares of Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.
In related news, CEO Stephen Christopher Linthwaite bought 45,000 shares of the stock in a transaction on Tuesday, August 8th. The stock was bought at an average price of $2.66 per share, with a total value of $119,700.00. Following the completion of the purchase, the chief executive officer now directly owns 106,977 shares in the company, valued at approximately $284,558.82. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Evan/ Fa Jones sold 10,900 shares of the stock in a transaction dated Wednesday, June 7th. The stock was sold at an average price of $4.54, for a total transaction of $49,486.00. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 4,105,573 shares of company stock valued at $13,494,381. 4.70% of the stock is currently owned by insiders.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
What are top analysts saying about Fluidigm Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Fluidigm Corporation and related companies.